Who Pays When Clinical AI Fails? The AMA's Blueprint for Medical Malpractice

Sam: Imagine being sued for a patient injury caused by a software error you could not have detected, working with a system you had no authority to decline. That is the exact nightmare keeping doctors awake at night. In the AMA's 2026 Physician Survey on Augmented Intelligence, respondents selected clear liability frameworks as the regulatory action most likely to increase their trust in AI and their likelihood of adopting it. Welcome to Smart Summaries. I am Sam, and today we are looking at the legal guardrails of algorithmic care.

Maya: And I am Maya. Just a quick reminder right at the top, our voices are AI-generated, and this is a summary of a publicly available document. To tackle this massive concern regarding medical malpractice, we are unpacking a highly anticipated issue brief published by the American Medical Association in October 2026. It is titled, Issue Brief: Liability for Clinical AI. It was produced by the AMA Center for Digital Health and AI, and it argues that the current legal landscape is completely inadequate for these new technologies. It pushes for a radical realignment of who holds the financial and legal risk when algorithmic recommendations result in patient harm.

Sam: That is a fundamental shift in how we think about medical liability. So, Maya, this document outlines several key issues in the current liability landscape. Where does the AMA say the primary concern lies right now for individual clinicians?

Maya: The primary issue they highlight is that physicians may be held responsible for errors they cannot reasonably detect. Right now, doctors are often expected to rely on AI systems that they were not informed were in use, or had no authority to select or decline. The AMA points out that meaningful physician oversight depends entirely on conditions that physicians often do not control.

Sam: When the document says that meaningful physician oversight depends on conditions that physicians do not control, what does that actually look like in practice? If I am a clinician on a busy ward, what are these conditions that I am completely blind to when I am handed an AI tool by my health system?

Maya: The issue brief breaks those conditions down very clearly. They include what the developers choose to disclose, how the software interfaces actually present the outputs, whether the physicians even have the administrative authority to intervene, and whether the clinical workflows allow sufficient time and information for a proper review. Physicians often cannot inspect a model, see how it was validated, or know how it performs on their own specific patient populations.

Sam: That sounds like a recipe for legal disaster if a physician is on the hook for a system they cannot even look under the hood of. The brief gives specific examples of these undetectable errors to make it concrete. Can you walk us through the initial example they mention, which they call a triage error?

Maya: Absolutely. In the triage error scenario, the physician cannot see the AI decision at all. If a triage model deprioritizes a case behind the scenes, the physician sees only an order of patients presented on their screen. The physician may end up seeing that deprioritized patient hours later, with absolutely no way of knowing that the AI system actually caused the delay.

Sam: That is a terrifying scenario for any clinician. The AMA brief mentions another specific example called an upstream data error. How does that play out when a doctor is reviewing a patient chart?

Maya: An upstream data error happens when an AI system synthesizes records from multiple providers or patient inputs. It might generate a final output based on missing laboratory results, outdated diagnoses, or incomplete historical information. The final output may appear clinically plausible to the physician. Even when it is based on incomplete or inaccurate information, the physician cannot reasonably identify or verify that the underlying inputs were flawed.

Sam: So the clinician reads a summary, it makes total clinical sense, but it is built on fabricated or missing details that look entirely consistent with the record they reviewed. That is exactly why the AMA writes that vigilance alone cannot substitute for evidence and design. You cannot expect a doctor to catch an error that is perfectly camouflaged by the software design.

Maya: Exactly. And that brings us to another key issue in the current landscape, which focuses on the organizations that actually buy and implement these tools. The text states that deployers' AI-specific responsibilities remain unsettled. Healthcare organizations that deploy AI control many of the conditions that shape its use, but their exact legal obligations regarding these tools are still incredibly murky.

Sam: Let us unpack those deployer responsibilities. What exactly does a healthcare organization control that shapes the use of clinical AI? Because we know hospitals buy equipment all the time, but software feels like a completely different paradigm.

Maya: According to the document, deployers control tool selection, vendor contracts, interface configuration, staffing, training, the time allotted for review, and post-deployment monitoring. Healthcare organizations already owe duties of care for equipment acquisition, staffing, physician credentialing, oversight, and policies. While the scope of those duties varies by state, what remains largely unsettled right now is how those exact duties apply to artificial intelligence.

Sam: So a hospital knows exactly how to credential a new surgeon, but they do not have established legal frameworks for credentialing a new algorithm. The brief highlights several open questions for deployers. It lists qualification or credentialing of AI systems, local testing, version updates, user training, safety and outcomes monitoring, incident response, and decisions about when to take a tool out of service.

Maya: It really is an unsettled area. And that leads directly into the next key issue, which is the uncertainty around when product liability applies to AI. Developers control a tool's design, development, labeling, and warnings. While traditional product liability law can hold manufacturers responsible for defective designs and inadequate warnings, it is completely unsettled whether those rules reach software, and specifically which AI systems they cover. The application varies entirely by jurisdiction.

Sam: And the brief makes a very sharp point here for companies building these tools. It states that a tool's regulatory status does not settle its legal status. Just because an AI system cleared a regulatory hurdle does not mean the developer is shielded from product liability if something goes wrong. Which transitions perfectly into how developers and deployers are currently trying to handle this uncertainty through their business contracts.

Maya: Yes, the issue is that contract terms and disclaimers can shift responsibility without reflecting who actually has control over the risk. Contracts between developers and deploying organizations often allocate financial responsibility for AI-related harm through indemnification provisions, liability limits, and other terms. The AMA notes that these arrangements can place responsibility on parties who have little to no ability to actually identify, prevent, or mitigate the harm.

Sam: It is essentially a high-stakes game of hot potato with legal liability, and the individual physician is usually the one left holding it. The brief also mentions that patient- and physician-facing terms may restrict dispute resolution options or limit legal claims for injuries. Which brings us to the final issue in the current landscape: some patients may have no clear path to recovery.

Maya: That is the ultimate tragedy of this unsettled landscape. The AMA notes that not every patient injury results from a failure for which a party is legally responsible, even when AI is involved. But when harm does result from defective technology, negligent implementation, or other actionable failures, establishing responsibility can be incredibly difficult. The responsibility is distributed across parties, obscured within systems, or artificially limited by contract. Patients harmed by these failures should have meaningful avenues for redress.

Sam: So we have physicians held accountable for invisible errors, deployers with unsettled duties, developers with unclear product liability, contracts shifting blame unfairly, and patients left without a path to recovery. That is a massive mess. How is the AMA Center for Digital Health and AI proposing to actually fix this?

Maya: Their solution is anchored in a core principle from AMA Policy H-480.939. The policy states that liability and incentives should be aligned so that the individuals or entities best positioned to know the AI system risks and best positioned to avert or mitigate harm do so through design, development, validation, and implementation. The Center applies this by aligning accountability strictly with each party's authority, access to information, and ability to prevent or mitigate harm.

Sam: That makes perfect logical sense. You are responsible for the parts you actually control. The brief breaks this down into distinct categories: Physicians, Developers, and Deployers. Where control is shared, responsibility is shared, but it does not become interchangeable. Let us start with the physicians. What is their exact scope of responsibility under this new framework?

Maya: The rule for physicians is crisp: Physicians are responsible for the clinical judgment they can meaningfully exercise. The Center argues that clinical authority must be earned through evidence and maintained through demonstrated performance. Where evidence is insufficient or does not apply to the intended clinical setting, deployment should be reconsidered.

Sam: I want to dig into that phrase, meaningful physician oversight. What does the AMA say is actually required for oversight to be considered meaningful on a busy clinical ward? Because we established earlier that just putting an AI recommendation on a screen is not enough.

Maya: Quick note before we carry on. This spot is open for a sponsor. If your company builds or sells AI for healthcare and wants to reach the clinicians, health-system leaders and industry teams who listen to this show, the link to our sponsorship page is in the show notes.

Sam: And now, back to the document.

Maya: Meaningful physician review requires very specific conditions. Physicians need the right information, at the right time, in a form they can act on. It depends on access to sufficient information to evaluate an AI system's output in the relevant clinical context, alongside the time, training, and authority to act on it. The AMA explicitly states that these conditions cannot be assumed simply because a physician is presented with an AI-generated result.

Sam: And this ties directly back to what a physician could reasonably detect. The brief references AMA Policy H-480.931(5)(b), which says physicians should not be held liable for the performance of an AI-enabled technology when they do not know or have reason to know of concerns about its quality and safety. When does the AMA say it is actually reasonable for a doctor to just trust the AI?

Maya: Reasonable reliance is supported when AI systems perform a defined clinical function, have demonstrated performance for that function in comparable settings, provide outputs physicians can meaningfully evaluate and act upon, and undergo changes through controlled, documented processes. Regulatory authorization can also support a finding of reasonable reliance when an AI system is used within its authorized intended use and under conditions consistent with its validation.

Sam: But they also outline conditions that limit reasonable reliance, right? Like when an AI system's performance has not been adequately characterized for the clinical function at issue, or when errors cannot reasonably be identified through the available information and clinical workflow. That goes back to the fabricated detail in a clinical summary looking entirely consistent with the record the physician reviewed.

Maya: Exactly. And because of those limitations, the AMA strongly asserts that physicians should be free to decline unproven AI. They should retain the authority to decline AI systems whose clinical validation, usefulness, or place in the standard of care remains uncertain, without being penalized for exercising their clinical judgment.

Sam: Let us pivot to the companies building these tools. The rule for developers is that they are responsible for what they design and build. How does the AMA define the scope of a developer's responsibility in this brief?

Maya: Developers play a central role because they make the design and development decisions that shape how AI systems function, the risks they introduce, and whether users can detect and respond to errors. These include crucial decisions about training and validation data, system architecture, intended use, interfaces, and the specific information made available to users. Developers remain entirely responsible for the risks arising from what they control.

Sam: And the brief takes a very hard stance on developers trying to shift responsibility to physicians. They state that physician oversight should not serve as a blanket justification for transferring responsibility or liability for AI-related harm. It explicitly says that warnings and labeling alone cannot establish the conditions necessary for meaningful physician oversight. Doctors need usable information about intended use and performance, not just legal disclaimers.

Maya: That is a critical point. The brief holds that transparency requirements should be designed to meet the needs of the end users. Documentation and disclosure should enhance patient and physician knowledge without increasing administrative burden. Furthermore, developer responsibilities do not just end when the software is sold. Their duties continue after deployment, proportionate to their control over its design, performance, and associated risks.

Sam: Now let us look at the deployers, which refers to the health systems, hospitals, and physician practices introducing AI into clinical care. The AMA says their responsibilities are distinct from developers and physicians, and they complement them. The rule here is that deployers are responsible for where and how AI is put to work. What does their institutional duty of care actually look like?

Maya: Deployers must have fit-for-purpose processes for specific actions: evaluating and selecting AI systems, validating their performance in the intended clinical setting, monitoring safety and performance, and responding to emerging risks. The brief notes that training should prepare physicians to use technology as intended, and disclosures should be calibrated to the setting, so that physicians are not left to filter excessive or extraneous information.

Sam: And what about when the software gets updated? We all know that machine learning models change over time. Does the hospital bear the risk every time a vendor pushes a new software update?

Maya: The brief specifically addresses modifications and updates. Deployers are responsible for the implementation decisions and modifications strictly within their control. Liability exposure should reflect the nature of the change. A routine configuration differs entirely from a material modification that alters a system's function or performance. Deployers need to understand how updates are managed, including exactly which changes they control, and establish appropriate processes for assessing the implications.

Sam: They also mention information flow and corrective action. Deployers are expected to ensure that safety and performance information actually moves between the developers building the tool, the clinicians using it, and the appropriate oversight bodies.

Maya: Yes, and all of these frameworks ultimately point toward the final stakeholder: the patient. The AMA insists we must preserve patients' path to recovery. Protecting physicians who rely appropriately on AI must go hand in hand with clear expectations for developer and deployer accountability. Otherwise, patients may be left without recourse when harm results from failures for which those parties are actually responsible.

Sam: The brief is very clear on developer responsibility for defects. Patients harmed by defective AI systems should have meaningful avenues to pursue remedies from the responsible developers. Liability frameworks need to account for the developer's role in creating and controlling the relevant risks, and the AMA even suggests that recovery without proof of negligence may be appropriate in some circumstances.

Maya: They also touch on patient-facing terms. Disclaimers, consent forms, and other patient-facing terms should never be used to eliminate or improperly restrict patients' legal remedies for injuries resulting from defective AI systems or other actionable failures in their care. The accountability must remain intact regardless of the paperwork signed at the front desk.

Sam: That is a massive shift in how medical liability is traditionally conceptualized. Before we wrap up, the document ends with a section titled What's Next. It lists priority areas that the AMA Center for Digital Health and AI will focus on moving forward as clinical AI capabilities advance. What is the initial priority on their radar?

Maya: The initial priority area is increasingly autonomous AI. As AI systems assume more consequential clinical functions with less direct physician oversight, they are asking how liability for patient harm should be allocated. Key questions include the authorization to perform clinical functions and the respective obligations of the developers and the deploying organizations when the human is mostly out of the loop.

Sam: The next priority deals with automation bias and meaningful oversight. They want to know how liability frameworks should account for foreseeable automation bias on AI systems, particularly those that perform reliably most of the time. They are asking what responsibilities developers and deployers have to design systems and workflows that actually support meaningful physician oversight in the face of that psychological bias.

Maya: Another area is patient information and consent. The AMA wants to clarify exactly when patients should be informed that AI is being used in their care, and when formal informed consent is appropriate.

Sam: The subsequent priority is information sharing and safety reporting. What specific information about AI performance, limitations, errors, and adverse events should developers and deployers share with physicians, patients, regulators, and one another?

Maya: The following priority is crucial for health system leaders. It focuses on practical implementation and economic sustainability. The AMA is asking how liability and oversight expectations can be right-sized for practices and health systems with vastly different resources and capabilities.

Sam: And the final of the priority areas is data privacy, cybersecurity, and liability. They want to determine how liability for patient harm arising from AI-related privacy or cybersecurity failures should be allocated among developers, deployers, and physicians.

Maya: These priorities will guide the Center's work to convene stakeholders, address evidence gaps, and shape policy as clinical AI evolves. Their ultimate conclusion is powerful: as AI assumes increasingly consequential functions in clinical care, accountability must evolve alongside clinical authority. Getting this right is essential to earning the trust of both patients and physicians, enabling responsible innovation, and actually translating AI's capabilities into better patient care.

Sam: That is a perfect summary. The AMA is drawing a hard line: physicians are only responsible for the clinical judgment they can meaningfully exercise; developers and deployers must own the risks within their control; and patients must always have a path to redress. That wraps up our deep dive into the AMA's October 2026 Issue Brief on Liability for Clinical AI. Just a reminder that this podcast is not medical advice, and you can find a link to the full source document in the show notes. Thanks for listening.